Stevanato Group S.p.A. (STVN) 12-Month Stock Forecast & Price Target Cone

STVN scores 58 out of 100, equating to a D+ grade and the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 12/20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 11/20 (institutional accumulation and options positioning), Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 13/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillar is Insider Conviction, and the Cash Engine pillar is weak because the source reports ROIC and FCF yield at 0%. For a prospective investor, the pillar profile suggests that the operating return case is not yet visible in the data, that insider signals do not add support, and that the balance-sheet metrics (Altman Z 2.5, Piotroski F 6/9) are moderate rather than strong. A Beta of 1.0 means the source characterizes the stock as moving in line with the broad market, so the rating does not rest on a volatility argument. The verdict is a quantitative summary of the supplied data, not a recommendation.

Stevanato Group S.p.A. Is a NYSE-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry,. — for products sold, customer base, or revenue model.

ROIC is reported at 0% and the FCF yield at 0%. Gross, operating, and net margins are each reported at 0% in the market data section. Per the RQD rating's forensic pillar, the Altman Z-Score is 2.5, the Piotroski F-Score is 6/9, and Debt/Equity is 0.5.

• 🐂 Primary Bull Case: Per the RQD rating, the Altman Z 2.5 and Piotroski F 6/9 forensic readings are moderate, and the stock trades at $20.24 within a $17.55–$22 52-week range. With Fundamental Cash Engine at 12/20 (ROIC —, FCF yield —) and Institutional Whale Flow at 8/20, sustained execution supports upside toward the top of the $12.89 – $27.00 52-week range.
• 🐻 Primary Bear Case: Per the RQD rating, ROIC and FCF yield are both 0%, and the Insider Conviction pillar scores only 9/20. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Sector is Health Care and industry is Medical/Dental Instruments.

• Key Question #1: Why are ROIC and FCF yield both reported as 0%, and is this a data gap or an actual absence of returns?
• Key Question #2: What are the P/E, forward P/E, and EV/EBITDA multiples, which are all unavailable?
• Key Question #3: What institutional (13F) and insider (Form 4) transactions have occurred, given the holders section is empty?